Holen Sie sich die Stockscreener-App
60.06
0.27%
0.16
Handel nachbörslich:
61.85
1.79
+2.98%
Schlusskurs vom Vortag:
$59.90
Offen:
$60.99
24-Stunden-Volumen:
30,028
Relative Volume:
0.72
Marktkapitalisierung:
$64.29M
Einnahmen:
$697.00K
Nettoeinkommen (Verlust:
$-38.97M
KGV:
-2.0657
EPS:
-29.075
Netto-Cashflow:
$-33.33M
1W Leistung:
+7.50%
1M Leistung:
-9.40%
6M Leistung:
-88.95%
1J Leistung:
-90.34%
1-Tages-Spanne:
$57.00
$62.25
1-Wochen-Bereich:
$52.47
$68.10
52-Wochen-Spanne:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
60.06 | 64.12M | 697.00K | -38.97M | -33.33M | -29.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Spruce Biosciences names Dale Hooks as chief commercial officer - Investing.com Nigeria
HC Wainwright Issues Optimistic Outlook for SPRB Earnings - MarketBeat
SPRB: Citizens Lowers Price Target but Maintains Market Outperfo - GuruFocus
SPRB: Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum - TradingView
Spruce Biosciences (NASDAQ:SPRB) Announces Quarterly Earnings Results - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Given New $170.00 Price Target at Citizens Jmp - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Earns "Buy" Rating from HC Wainwright - MarketBeat
SPRB: HC Wainwright & Co. Reiterates Buy Rating with $200 PT | S - GuruFocus
Spruce Biosciences (SPRB) Chief Commercial Officer files Form 3 - Stock Titan
Spruce Biosciences Reports 2025 Financial Results, Advances TA-ERT for MPS IIIB with FDA, and Secures $50M Growth Capital - Minichart
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Com - PharmiWeb.com
Spruce Biosciences, Inc. 2024 Annual Report: Business Overview, Risk Factors, Pipeline, and Regulatory Updates - Minichart
SPRB: TA-ERT program progresses toward BLA submission as net loss narrows and cash runway extends - TradingView
Spruce Biosciences Appoints Dale Hooks as Chief Commercial Officer - Contract Pharma
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates - pharmiweb.com
According to the latest documents submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Spruce Biosciences, Inc. has been authorized to offer and sell its common stock under the current sales agreement, with the tota - Bitget
Spruce Biosciences Updates ATM Agreement, Strengthens Leadership Team - TipRanks
Spruce Biosciences 10-K: $0.0M Revenue, $(50.83) EPS on $(39.0)M Net Loss - TradingView
Spruce Biosciences Launches New ATM Equity Program With Jefferies - TradingView
Spruce Biosciences, Inc. recently announced the official appointment of Dale Hooks, who has outstanding achievements in the commercialization of rare diseases, as the company's Chief Commercial Officer. - Bitget
Spruce Biosciences 2025 net loss narrows, secures $50 mln funding - TradingView
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer - Bluefield Daily Telegraph
Spruce Biosciences (SPRB) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway - Yahoo Finance
12 Most Promising Micro-Cap Stocks According to Analysts - Insider Monkey
SPRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
SPRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SPRB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Spruce Biosciences to Present at Upcoming Investor Conferences in March 2026 - BioSpace
Spruce Biosciences to Present at Upcoming Investor Conferences in March - Investing News Network
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Analysts - MarketBeat
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference - MarketBeat
Spruce Biosciences Inc. (SPRB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Total debt per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
Carlyle Group Inc. Expands Stake in Spruce Biosciences Inc. - GuruFocus
Millennium group (SPR B) joint Schedule 13G shows ~103K shares (~9.6%) - Stock Titan
HC Wainwright Has Positive Outlook for SPRB FY2025 Earnings - MarketBeat
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Regulatory De-Risking and Extended Runway Underpin Maintained Buy Rating on Spruce Biosciences - TipRanks
SPRB Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus
Carlyle Group Inc. Takes Position in Spruce Biosciences, Inc. $SPRB - MarketBeat
Spruce Biosciences Stock Falls 5% Despite Positive Outcomes From Two Recent Type B Meetings With FDA - Nasdaq
Spruce Biosciences Gains After Positive FDA Type B Meetings On TA-ERT - Nasdaq
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
Spruce Biosciences, Inc. shares recorded a significant increase, rising by 8.16% in a single day. - Bitget
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Investing News Network
Biotech working on neurological drugs joins Oppenheimer stage - Stock Titan
Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA). - Bitget
SPRB PE Ratio & Valuation, Is SPRB Overvalued - Intellectia AI
SPRB Should I Buy - Intellectia AI
Spruce Biosciences: TA-ERT’s Promising Long-Term Data and Priority Review Voucher Upside Underpin Reiterated Buy and $220 Target - TipRanks
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):